Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary ViewRay® to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
CLEVELAND , Nov. 20, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the 2019 Piper Jaffray 31 st Annual Healthcare Conference in New York, New York . Scott Drake , President and CEO, will give a presentation at 1:30p.m.
Toggle Summary ViewRay Reports Third Quarter 2019 Results
CLEVELAND , Nov. 12, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Summary: Total revenue was $20.9 million in the quarter, primarily from three revenue units, compared to $17.7 million ,
Toggle Summary European Symposium to Advance Adoption of MRI-Guided Radiation Therapy
Educational Event to Feature Presentations from MRIdian® Users and ESTRO Past President on the Strategic, Economic, Clinical and Technical Aspects of MRI-Guided Radiation Therapy CLEVELAND , Oct. 24, 2019 /PRNewswire/ -- Clinicians interested in learning more about MRI-guided radiation therapy can
Toggle Summary ViewRay Announces Preliminary Third Quarter 2019 Results and Details of Upcoming Conference Call
CLEVELAND , Oct. 15, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019. The preliminary results have not been audited and are subject to change. Selected Third Quarter Preliminary Results: Total revenue of $20.9 million in the third

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449

In Need of Customer Support? Contact

  Language Select